Research programme: bradykinin B1 receptor antagonists - Evotec AG
Latest Information Update: 16 Jul 2016
At a glance
- Originator Evotec AG
- Class Small molecules
- Mechanism of Action Bradykinin B1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany (PO)
- 09 Sep 2010 Preclinical trials in Pain in Germany (PO)